In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Harrow Health, with a price target of $69.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors, primarily driven by Harrow Health’s strong financial performance and strategic initiatives. The company reported a significant year-over-year revenue growth of 45.4% in the third quarter of 2025, surpassing expectations. Despite a net income miss due to a debt extinguishment loss, the growth in key product lines like VEVYE and IHEEZO demonstrates promising market traction.
Additionally, Harrow Health’s strategic moves, such as the VEVYE Access for All program and new payer agreements, are expected to enhance patient access and drive further growth. The anticipated revenue range for 2025 indicates a robust 38% growth, and the company’s expansion plans, including new product launches in 2026, are likely to sustain this momentum. These factors contribute to the revised price target of $69 per share, reinforcing the Buy rating.